Details of the position and how to apply are here.
This study introduces endogenous ADA2 expression as a prognostic factor and PEGADA2 as a novel immunotherapy for cancer. Read the article here.
Dr. Sahin gave a talk on “Targeting LOX in chemoresistance and developing novel LOX inhibitors” at the ACS Mini Symposium
Dr. Sahin co-organized a Mini Symposium with Dr. Taru Muranen (Dana-Farber Cancer Institute) and Rebeca San Martin (University of Tennessee, Knoxville) which was hosted by Joe Cotter from the American Cancer Society – February 17, 2021. The Mini Symposium was on “Tumor microenvironment in the context of drug resistance and Read more…
Dr. Sahin presented our recent work on how we take genome/transcriptome-wide approaches to identify regulators of drug resistance, identify mechanisms of resistance and develop novel drug candidates on Feb 12, 2021 at the Seminar Series of Izmir Biomedicine and Genome Center (IBG), which is a leading biomedical center in Turkey.
AACR Virtual Special Congress, “The Evolving Tumor Microenvironment in Cancer Progression; Mechanisms and Emerging Therapeutic Opportunities” – January 11-12, 2021, brought together experts from diverse fields to thoroughly explore and discuss the topic. Dr. Sahin gave a “Lightning Talk” on the role of LOX in chemoresistance.
Dr. Sahin gave a talk entitled “From mechanisms of drug resistance to drug discovery” at the 8th Multidisciplinary Cancer Research Congress held by Istinye University, Istanbul – January 16, 2021. The talk was well received by the audience with multiple questions and comments from students to experts in the field.
Our project aiming at overcoming chemotherapy resistance in TNBC via targeting lysyl oxidase (LOX) was chosen for presentation at National NIGMS IDeA Program Virtual Meeting – September 22, 2020. Our discovery of this novel drug resistance mechanism was recently published in one of the most selective and prestigious scientific journals Read more…
Our latest article has been published in Nature Communications. The study focuses on the identification of lysyl oxidase (LOX) protein as a major chemotherapy resistance modulator in triple negative breast cancer. We showed that targeting LOX overcomes chemoresistance in TNBC. Read the article here.
Dr. Sahin received the prestigious American Cancer Society Research Scholar Grant. The grant, totaling nearly $800,000 over the next four years, will support our research on overcoming tamoxifen resistance and blocking metastasis in breast cancer. Our hope is that the research results from this grant will lay the foundation for Read more…